Wegovy Savings Card vs Compounded: Which Saves More?
Compare the Wegovy savings card with compounded semaglutide. Discover which option truly saves more for patients with and without insurance in 2026.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. This analysis compares the Wegovy savings card program with compounded semaglutide to determine which truly saves patients more money.
Quick links: Semaglutide treatment, tirzepatide treatment, and best GLP-1 provider guide.
More on GLP-1 Provider Comparisons
Understanding the Wegovy Savings Card
The Wegovy savings card is a manufacturer-sponsored copay assistance program from Novo Nordisk designed to reduce the out-of-pocket cost of brand-name Wegovy for eligible patients. On paper, the program sounds generous — and for patients who qualify, it can meaningfully reduce monthly costs. However, the eligibility requirements, benefit caps, and fine print mean that the savings card is not a universal solution to Wegovy's high price.
The most important limitation is that the savings card requires commercial insurance that already covers Wegovy. It does not transform an uninsured patient into one who can afford Wegovy — it supplements existing coverage by reducing the copay portion. Patients without insurance, those on government insurance programs (Medicare, Medicaid, Tricare), and those whose commercial plans do not cover Wegovy cannot use the card at all.
This means the savings card helps a relatively narrow population: commercially insured patients whose plans cover Wegovy but impose copays that make the medication expensive. For everyone else — which represents the majority of people seeking semaglutide for weight loss — the savings card offers no benefit, and compounded semaglutide through Trimi remains the most affordable access pathway.
Side-by-Side Cost Comparison
| Scenario | Wegovy + Savings Card | Compounded Semaglutide |
|---|---|---|
| Insured, plan covers Wegovy | $0 - $25/mo (while card active) | $149/mo |
| Insured, plan does NOT cover Wegovy | Card not usable — $1,300+/mo | $149/mo |
| Uninsured | Card not usable — $1,300+/mo | $149/mo |
| Medicare/Medicaid | Card not usable — varies | $149/mo |
| After savings card cap reached | $200 - $500/mo (insurance copay) | $149/mo |
| Annual total (insured, card works all year) | $0 - $300/yr + insurance premiums | $1,788/yr |
| Annual total (uninsured) | $15,600+/yr | $1,788/yr |
Key Takeaway
The savings card wins only for commercially insured patients whose plans cover Wegovy and who do not exhaust the benefit cap. For every other scenario, compounded semaglutide is significantly more affordable.
When the Savings Card Makes Sense
To be fair, the Wegovy savings card is a valuable tool for patients who qualify. If you have commercial insurance that covers Wegovy, the savings card can reduce your monthly copay to near zero — making brand-name Wegovy essentially free beyond your regular insurance premiums. For this specific population, the savings card plus insurance is the least expensive way to access semaglutide.
You have commercial (employer or marketplace) insurance that covers Wegovy
Your plan requires a copay rather than covering Wegovy at 100%
You have not yet reached the savings card annual benefit cap
The savings card program is currently active and accepting enrollments
You do not mind the potential for the program to change or end
When Compounded Semaglutide Makes Sense
For the majority of patients — those without commercial insurance that covers Wegovy — compounded semaglutide is the clear winner on cost. It is also the better choice for patients who value predictability, simplicity, and independence from insurance and manufacturer programs that can change.
You do not have insurance, or your insurance does not cover Wegovy
You are on Medicare, Medicaid, or other government insurance
Your insurance copay for Wegovy exceeds $149 per month even with the savings card
You prefer predictable monthly pricing not subject to program changes
You want to avoid the hassle of prior authorization and insurance appeals
You value month-to-month flexibility without contracts or coverage requirements
You have experienced Wegovy supply shortages affecting your treatment
You want specialized weight management support from board-certified providers
Through Trimi, compounded semaglutide at $149 per month includes everything — medication, provider consultations, medical oversight, and shipping. No insurance needed, no savings cards to manage, no annual benefit caps to worry about. Just consistent, affordable access to the same active ingredient that makes Wegovy effective.
The Hidden Risks of Relying on Savings Cards
Patients who rely on manufacturer savings cards should be aware of several risks that can disrupt their treatment and finances unexpectedly.
Programs can be modified or discontinued by the manufacturer at any time
Annual benefit caps mean costs can spike partway through the year
Insurance coverage changes at annual renewal can affect savings card eligibility
Job changes or insurance plan switches can eliminate eligibility overnight
The savings card creates dependency on a promotional program rather than sustainable pricing
Compounded semaglutide pricing through Trimi is not dependent on any promotional program, insurance coverage, or manufacturer goodwill. The price reflects the actual cost of the medication and service, making it a sustainable long-term solution rather than a temporary promotional benefit.
Bottom Line
The Wegovy savings card is valuable for the specific subset of patients who have commercial insurance covering Wegovy. For everyone else — uninsured patients, those on government insurance, those whose plans do not cover Wegovy, and those who have exceeded their savings card benefit — compounded semaglutide at $149 per month through Trimi is the most affordable and reliable way to access the same medication.
Even patients currently using the savings card should have a backup plan. If your insurance changes, the program ends, or you hit the annual cap, knowing that compounded semaglutide is available ensures you can continue treatment without interruption. For many patients, the simplicity and predictability of compounded pricing makes it the preferred choice from day one.
Frequently Asked Questions
How does the Wegovy savings card work?
The Wegovy savings card from Novo Nordisk reduces the copay for commercially insured patients who have insurance coverage for Wegovy. When eligible, the card can bring monthly copays as low as $0 to $25. However, the card requires commercial insurance that covers Wegovy as a prerequisite, has a maximum annual benefit cap, and is not available to patients on Medicare, Medicaid, or those without insurance.
Can I use the Wegovy savings card without insurance?
No, the Wegovy savings card requires commercial insurance coverage for Wegovy. Patients without insurance cannot use the savings card. For uninsured patients, compounded semaglutide through providers like Trimi at $149 per month is the most affordable way to access the same active ingredient without needing insurance coverage.
Does the Wegovy savings card have a maximum benefit?
Yes, the Wegovy savings card has a maximum annual benefit amount, after which patients revert to their standard insurance copay. The specific maximum varies by program terms and can change. Once the cap is reached, patients may face significantly higher costs for the remainder of the year. Compounded semaglutide pricing remains consistent month to month without any benefit caps.
Is compounded semaglutide cheaper than Wegovy with the savings card?
It depends on your insurance situation. For patients who qualify for the savings card and have insurance that covers Wegovy with a low copay, the savings card may result in lower monthly costs. However, for patients without insurance, those whose insurance does not cover Wegovy, or those who exceed the savings card benefit cap, compounded semaglutide at $149 per month is typically less expensive.
Who qualifies for the Wegovy savings card?
Eligibility typically requires commercial insurance that covers Wegovy, US residency, and being 18 or older. Patients on Medicare, Medicaid, Tricare, or other government-funded insurance programs are generally excluded. Patients whose insurance does not cover Wegovy or who have no insurance are also ineligible. Eligibility criteria can change, so always verify current requirements on Novo Nordisk's website.
Can the Wegovy savings card expire or be discontinued?
Yes, savings card programs have expiration dates and Novo Nordisk can modify or discontinue the program at any time. Patients relying on the savings card should be aware that their cost could increase significantly if the program changes. Compounded semaglutide through Trimi offers consistent, predictable pricing that does not depend on manufacturer promotional programs.
What happens when my Wegovy savings card benefit runs out?
When you reach the maximum annual benefit, you revert to your insurance plan's standard copay for Wegovy, which could be $200 to $500 or more per month depending on your plan. At that point, many patients find that switching to compounded semaglutide at $149 per month through Trimi is more cost-effective than continuing to pay the unsubsidized copay for brand-name Wegovy.
Sources & References
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication. Trimi offers compounded semaglutide — readers should be aware of our perspective.